J&J, Gen­mab re­veal first-line da­ta for Darza­lex Faspro, plus new man­tle cell lym­phoma re­sults for Im­bru­vi­ca-Ven­clex­ta: #ASH23

The late-break­ing ab­stracts for next month’s Amer­i­can So­ci­ety of Hema­tol­ogy meet­ing in San Diego were re­leased Tues­day morn­ing. Here are three no­table stud­ies from drug­mak­ers test­ing ther­a­pies in dif­fer­ent blood can­cers and dis­or­ders:

J&J, Gen­mab re­veal first-line da­ta for Darza­lex Faspro in mul­ti­ple myelo­ma: Re­searchers have been at­tempt­ing to move Darza­lex Faspro, the sub­cu­ta­neous ver­sion of the can­cer ther­a­py Darza­lex, in­to ear­li­er lines of treat­ment. John­son & John­son on Tues­day re­port­ed da­ta from a Phase III tri­al dubbed PERSEUS com­par­ing the treat­ment to the stan­dard of care in the front­line set­ting. Darza­lex Faspro on top of the stan­dard of care sig­nif­i­cant­ly im­proved pro­gres­sion-free sur­vival (PFS) rates in 709 pa­tients af­ter 47.5 months. Me­di­an PFS was not reached in ei­ther arm, but the ther­a­py record­ed a haz­ard ra­tio of 0.42 and a p-val­ue of p<0.0001.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER